Thursday, 21 February 2019


Sort by: Newest firstOldest firstA-ZZ-A

  • Credit where it's due

    Rumblings of discontent are spreading through Asia’s credit markets. Rather than cause for alarm, however, recent hiccups are a welcome reminder that not all credits are created equal.

  • Not-so-cheap money

    The era of cheap money was supposed to have ended several times already, but perhaps the message has finally reached the Asian bond market.

  • Biotech hazards

    Hong Kong’s biotech IPO rush may end up doing more harm than good. Even before the exchange has finalised its new rules exempting biotech companies from the usual profit and revenue tests, the long list of potential floats is prompting talk of a bubble.

  • Bond buyer beware

    Supply pressures are mounting in Asia’s bond markets. Borrowers will need to be careful not to get caught in the crush.

  • Xiaomi the money

    Xiaomi’s pending IPO is set to be a defining moment for China’s capital markets ambitions. It’s still not clear, however, which way it will go.

  • Capital calamity

    When it comes to bank capital, India’s central bank has often been guilty of drafting ambiguously worded regulations that create unnecessary confusion. Even by its own standards, however, its latest move will take some beating.

  • Foxconn fightback

    China is fighting back in the battle for technology listings. Just as the Hong Kong stock exchange unveils its proposals to allow dual-class shares, Shanghai is preparing for the IPO of Foxconn Industrial Internet.

  • Hong Kong Stuey

    All political lives, unless they are cut off in midstream at a happy juncture, end in failure.

  • D-share dreams

    Plans to launch a new class of Chinese shares in Germany are gaining traction, but it would be a mistake to assume that Frankfurt will one day rival Hong Kong or the US as a gateway for Chinese equities.

  • Jumping for junk

    In a rollercoaster week for global markets, the latest batch of Asian high-yield bonds deserves close attention.